In episode 155 Mike and James delve into the tricky area of the evidence around using antipsychotics as either monotherapy or augmentation for depression. We discuss that while there is evidence of benefit, the effect is not dissimilar to that seen with antidepressants.
1) Second-generation antipsychotics for major depressive disorder and dysthymia
2) Antipsychotics for depression: An acceptable risk/benefit profile?
3) Why Olanzapine Beats Risperidone, Risperidone Beats Quetiapine, and Quetiapine Beats Olanzapine